Guger, Michael http://orcid.org/0000-0001-8219-781X
Enzinger, Christian
Leutmezer, Fritz
Di Pauli, Franziska
Kraus, Jörg
Kalcher, Stefan
Kvas, Erich
Berger, Thomas
,
Funding for this research was provided by:
Biogen Austria
Merck Austria
Novartis Pharma Austria
Roche Austria
Sanofi/Genzyme Austria
Kepler Universitätsklinikum Linz
Article History
Received: 23 February 2021
Revised: 28 March 2021
Accepted: 10 April 2021
First Online: 22 April 2021
Declarations
:
: Michael Guger received support and honoraria for research, consultation, lectures and education from Almirall, Bayer, Biogen, Celgene, Genzyme, MedDay, Merck, Novartis, Octapharma, Roche, Sanofi Aventis, Shire and TEVA ratiopharm.Christian Enzinger received funding for travel and speaker honoraria from Bayer, Biogen, Genzyme, Merck, Novartis, Roche, Shire, and Teva Pharmaceutical Industries Ltd./Sanofi-aventis, research support from Biogen, Merck, and Teva Pharmaceutical Industries Ltd./Sanofi-aventis and serving on scientific advisory boards for Bayer, Biogen, Merck, Novartis, Roche and Teva Pharmaceutical Industries Ltd./Sanofi-Aventis.Fritz Leutmezer has received funding for travel and speaker honoraria from Actelion, Almirall, Bayer, Biogen, Celgene, Genzyme, MedDay, Merck, Novartis, Pfizer, Octapharm, Roche, Sanofi-Genzyme and Teva.Franziska Di Pauli has participated in meetings sponsored by, received honoraria (lectures, advisory boards, consultations) or travel funding from Bayer, Biogen, Merck, Novartis, Sanofi-Genzyme, Teva, Celgene and Roche. Her institution received scientific grants from Roche.Jörg Kraus received consulting and/or research funding and/or educational support from Almirall, Bayer, Biogen, Celgene, MedDay, Medtronic, Merck, Novartis, Roche, Sanofi-Aventis, Shire, TEVA ratiopharm.Stefan Kalcher, Erich Kvas declares that there is no conflict of interest.Thomas Berger has participated in meetings sponsored by and received honoraria (lectures, advisory boards, consultations) from pharmaceutical companies marketing treatments for multiple sclerosis: Almirall, Bayer, Biogen, Biologix, Bionorica, Genzyme, MedDay, Merck, Novartis, Octapharma, Roche, Sanofi/Genzyme, TG Pharmaceuticals, TEVA-ratiopharm and UCB. His institution has received financial support in the last 12 months by unrestricted research grants (Biogen, Bayer, Merck, Novartis, Sanofi/Genzyme, and TEVA ratiopharm) and for participation in clinical trials in multiple sclerosis sponsored by Alexion, Bayer, Biogen, Merck, Novartis, Octapharma, Roche, Sanofi/Genzyme, and TEVA.
: The AMSTR is compliant with Austrian laws on bioethics and it was also approved by the ethical committee of the Medical University of Vienna (EC number 2096/2013).